Le Lézard
Classified in: Health
Subject: FVT

Lipid-Based Drug Delivery in Modern Pharmaceutical Development to be Presented by Catalent and BASF at Forthcoming Workshop


SOMERSET, N.J., Sept. 20, 2018 /PRNewswire-PRWeb/ -- Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it will be co-hosting a workshop with BASF Corporation entitled "Revolutionary Then, Relevant Today: Lipid-Based Drug Delivery in Modern Pharmaceutical Development,". The one-day event is to be held at the Hilton Boston Back Bay hotel, Boston, Massachusetts, on Tuesday, Sept. 25.

The workshop will include scientific presentations from both academic and industry experts. Attendees will develop a better understanding of excipients, lipid-based drug delivery system (LBDDS) formulation development, and softgel technology, to help them overcome development challenges and advance their drug molecules into a drug product.

The presentation topics include:

For more information visit https://www.eventbrite.com/e/revolutionary-then-relevant-today-lipid-formulation-for-drug-development-tickets-48575540750

To arrange a meeting with any of the attending Catalent executives at the event, contact Richard Kerns at NEPR - [email protected]

About BASF Corporation
BASF creates chemistry for a sustainable future offering intelligent solutions to the pharmaceutical industry. With expertise in polymer chemistry, R&D-capabilities and commitment to developing excipients, BASF creates solutions for Instant & Modified Release, Solubilization, Softgels, Skin-Delivery and Biologics. BASF is also a leading supplier of selected APIs including ibuprofen and omega-3. For more information, visit http://www.pharma.basf.com.

About Catalent
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs over 11,000 people, including over 1,800 scientists, at more than 30 facilities across five continents, and in fiscal 2018 generated approximately $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com.

More products. Better treatments. Reliably supplied.tm

 

SOURCE Catalent, Inc.


These press releases may also interest you

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...

18 avr 2024
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: